

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-10. (Cancelled)

11. (Withdrawn) A method for treating neurodegenerative diseases involving protein aggregates, the method comprising:

administering the compound of formula (I)



(I)


wherein R' is an H, NH₂, or NHR² group, wherein R² is an alkyl or alkylaminoalkyl chain with 1 to 10 carbon atoms, branched or unbranched,

X represents F, Cl, Br, I, CF₃, SCH₃, OCH₃, OH, NO₂, COCH₃, CONH₂, COOH, or COOR³, where R³ is an alkyl group with 1 to 4 carbon atoms,

p and n, identical or different, are equal to 0, 1 or 2,
q is equal to 0 or 1.

12. (Withdrawn) A method for treating neurodegenerative diseases involving protein aggregates, the method comprising:

administering the compound of formula (III)




(III)

wherein R' represents an H, NH₂, NH-(CH₂)₃-N(CH₃)₂, or
NH-CH(CH₃)-(CH₂)₃-N(CH₂-CH₃)₂ group,

X represents F, Cl, or CF₃,

p and n, identical or different, are equal to 0, 1 or 2.

13. (Withdrawn and Currently Amended) A method for treating an animal or a human patient having a neurodegenerative disease disease protein aggregates responsive to treatment with an anti-prion agent, the method comprising [[:]] administering to said animal or said human patient a composition of claim 16
— administering the compound of formula (II)



(II)

— wherein R' represents an H, NH₂, NH-(CH₂)₃-N(CH₃)₂, or
NH-CH(CH₃)-(CH₂)₃-N(CH₂-CH₃)₂ group,

X represents F, Cl, or CF₃,

p and n, identical or different, are equal to 0, 1 or 2.


14. (Currently Amended) The method of claim 13 A method for treating an animal or a human patient having a neurodegenerative disease responsive to treatment with

an anti-prion agent, the method comprising administering to said animal or said human patient a composition of claim 17.

~~wherein R' represents an NH₂ group,
X represents F, Cl, or CF₃;
p and n, identical or different, are equal to 0, 1 or 2.~~

15. (Withdrawn and Currently Amended) The method of claim [[11]] 13, wherein the neurodegenerative diseases include: disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.

16. (Previously Presented) A pharmaceutical composition comprising:
a therapeutically effective quantity of at least one compound of formula (II)



wherein R' represents an NH₂, or NH-CH(CH₃)-(CH₂)₃-N(CH₂-CH₃)₂ group,

X represents F, Cl, or CF₃,

p and n, identical or different, are equal to 0, 1 or 2,

in combination with at least one pharmaceutically acceptable vehicle.

17. (Previously Presented) The pharmaceutical composition of claim 16
wherein in the compound of formula (II), R' represents an NH₂ group,
X represents F, Cl, or CF₃,
p and n, identical or different, are equal to 0, 1 or 2.


18. (Currently Amended) A method of treatment of an animal or human patient having a neurodegenerative disease, the method comprising the administration a administering to said animal or said human patient in need thereof of a therapeutically effective dose of a pharmaceutical composition of claim 16 for the treatment of said neurodegenerative disease.

19. (Currently Amended) The method of claim 18, wherein the pharmaceutical composition is administered to a patient suffering from a neurodegenerative disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.

20. (Currently Amended) A method of treatment of an animal or human patient having a neurodegenerative disease, the method comprising the administration a administering to said animal or said human patient in need thereof of a therapeutically effective dose of a pharmaceutical composition of claim 17 for the treatment of said neurodegenerative disease.

21. (Currently Amended) The method of claim 20, wherein the pharmaceutical composition is administered to a patient suffering from a neurodegenerative disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.

22. (Previously Presented) A pharmaceutical composition comprising: a therapeutically effective quantity of at least one compound of formula (II)



(II)

wherein R' is -NH-(CH₂)₃-N(CH₃)₂,
X is F, Cl, or CF₃, and
p and n, identical or different, are equal to 1 or 2,
in combination with at least one pharmaceutically acceptable vehicle.

23. (New) A method for treating an animal or a human patient having a neurodegenerative disease responsive to treatment with an anti-prion agent, the method comprising administering to said animal or said human patient a composition of claim 22.

24. (New) A method for treating an animal or a human patient having a neurodegenerative disease comprising administering to said animal or said human patient a therapeutically effective dose of a pharmaceutical composition of claim 22.

25. (New) The method of claim 24, wherein the neurodegenerative disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.

26. (New) The method of claim 14, wherein the neurodegenerative disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.

27. (New) The method of claim 22, wherein the neurodegenerative disease is selected from the group consisting of spongiform encephalopathies, Alzheimer's disease, Parkinson's disease and Huntington's disease.